Last reviewed · How we verify
NCT03824548
Outcomes for Patients With Gastro-Esophageal Reflux Disease
trial testing this is non-intervention study, there is no intervention drug or device in this study. in Gastro-esophageal Reflux Disease in 50,000 participants. Status unknown.
1 May 2019
Quick facts
| Lead sponsor | Tianjin Happy Life Technology Co., Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50,000 |
| Start date | 17 January 2019 |
| Primary completion | 1 May 2019 |
| Estimated completion | 1 May 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- this is non-intervention study, there is no intervention drug or device in this study.
Conditions studied
- Gastro-esophageal Reflux Disease — all drugs for Gastro-esophageal Reflux Disease →
Sponsor
Tianjin Happy Life Technology Co., Ltd.
Who can join
Eligibility, any sex, with Gastro-esophageal Reflux Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gastro-esophageal reflux disease (GERD), the most common cause of erosive esophagitis (EE), remains highly prevalent worldwide. GERD poses substantial burden on both patients and society. EE treatment patterns and unmet needs have been well-studied overseas, but evidence gaps still exist in China. To fill these evidence gaps, real-world evidence for GERD and EE are needed. To understand GERD market we will analysis :Patient profile,GERD patient journey within hospital (first present, get diagnosed, receive initial and maintenance treatment),medication cost,department differentiation. To investigate current treatment patterns of GERD / EE in China we will analysis: Current agents used and treatment duration in clinical practice treatment patterns by different reimbursement status treatment pattern by EE/NERD. To get healing rate of EE we will analysis: Real-world efficacy of the current standard treatment (i.e. PPIs) for patient with two test results of gastroscopy. The data required for this project are accessible in hospital electronic system; no specific data collection tools or methods are required for this project design. Only algorithms for retrieving and extracting eligible patients' records are required and will be developed by HLT based on the eligibility criteria defined in this protocol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03824548
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastro-esophageal Reflux Disease
Currently open trials in the same condition.
- NCT03596476 — Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Refl · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03824548 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Happy Life Technology Co., Ltd.
- Last refreshed: 31 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03824548.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing